An efficient continuous synthesis has been developed for nevirapine drug substance to convert starting materials into product in high yield (87% overall). The process employs inexpensive raw materials in flow to produce an active pharmaceutical ingredient (API) that meets or exceeds all USP specifications. This process utilizes two flow reactors; a Synthetron a spinning disk reactor and a Vapourtec E-Series flow reactor.

Nevirapine Continuous Report

Nevirapine Batch